Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Acta Haematologica"
DOI: 10.1159/000526979
Abstract: Introduction: Complement C5 inhibitor eculizumab is the first approved treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare hematologic disorder caused by uncontrolled terminal complement activation. Approximately 50% of patients with aplastic anemia (AA) have PNH… read more here.
Keywords: ist ecu; registry; ecu ist; paroxysmal nocturnal ... See more keywords